- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04637763
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
March 5, 2024 updated by: Caribou Biosciences, Inc.
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This clinical trial is a first-in-human, Phase 1, multicenter, open-label evaluation of safety and emerging efficacy of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma.
The study is conducted in two parts: Part A is dose escalation following a 3 + 3 design, with sequential, prespecified, increasing doses.
Part B is the expansion portion where patients will receive CB-010 at the dose determined in Part A.
Study Type
Interventional
Enrollment (Estimated)
72
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Socorro Portella, MD
- Phone Number: 973 866 7567
- Email: clinicaltrials@cariboubio.com
Study Locations
-
-
New South Wales
-
Westmead, New South Wales, Australia, 2145
- Recruiting
- Westmead Hospital
-
Contact:
- Dr Kenneth Micklethwaite
- Phone Number: +61 2 8890 5764
- Email: ken.micklethwaite@health.nsw.gov.au
-
Contact:
- Gillian Huang
- Phone Number: +61 2 8890 5448
- Email: gillian.huang@health.nsw.gov.au
-
-
Victoria
-
Richmond, Victoria, Australia, 3121
- Recruiting
- Epworth Healthcare
-
Contact:
- Dr Costas Yannakou
- Phone Number: (03) 9483 3833
- Email: costas.yannakou@epworth.org.au
-
Contact:
- Dr Connie Barlas
- Phone Number: (03) 95162374
- Email: connie.barlas@epworth.org.au
-
-
-
-
-
Jerusalem, Israel, 9112001
- Recruiting
- Hadassah Medical Center
-
Contact:
- Nurit Ben Shmuel
- Phone Number: +972 509508992
- Email: nuritb@hadassah.org.il
-
Petah Tikva, Israel, 4941492
- Recruiting
- Rabin Medical Center
-
Contact:
- Miri Pinhasov
- Phone Number: 972-3-9377909
- Email: miripi@clalit.org.il
-
Tel Aviv, Israel, 6423906
- Recruiting
- Tel Aviv Medical Center
-
Contact:
- Sandrine Harari-Csillag
- Phone Number: +972 36973186
- Email: sandrinehc@tlvmc.gov.il
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- University of Alabama at Birmingham
-
Contact:
- Amitkumar Mehta
- Phone Number: 205-996-8400
- Email: amitkumarmehta@uabmc.edu
-
-
Arizona
-
Gilbert, Arizona, United States, 85234
- Recruiting
- Banner MD Anderson Cancer Center
-
Contact:
- Tracy Kliner
- Phone Number: 480-256-4739
- Email: tracy.kliner@bannerhealth.com
-
Scottsdale, Arizona, United States, 85258
- Recruiting
- HonorHealth
-
Contact:
- Research Nurse Navigator
- Phone Number: 480-323-1364
- Email: clinicaltrials@honorhealth.com
-
Tucson, Arizona, United States, 85724
- Recruiting
- University of Arizona Cancer Center
-
Contact:
- Francois Chu
- Phone Number: 520-621-0823
- Email: fchu@arizona.edu
-
-
California
-
La Jolla, California, United States, 92073
- Recruiting
- University of California San Diego Moores Cancer Center
-
Contact:
- Michelle Padilla
- Phone Number: 858-822-5223
- Email: mlp002@health.ucsd.edu
-
Orange, California, United States, 92868
- Recruiting
- Chao Family Comprehensive Cancer Center/University of California Irvine
-
Contact:
- Blake Johnson
- Phone Number: 714-456-3476
- Email: blakej@hs.uci.edu
-
-
Florida
-
Orlando, Florida, United States, 32803
- Recruiting
- Advent Health
-
Contact:
- Kristen Wing
- Phone Number: 407-303-8251
- Email: Kristen.Wing@adventhealth.org
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Recruiting
- Bone and Marrow Transplant Group of Georgia
-
Contact:
- Melhem Solh, MD
- Phone Number: 404-255-1930
- Email: msolh@bmtga.com
-
Augusta, Georgia, United States, 30912
- Recruiting
- Georgia Cancer Center at Augusta University
-
Contact:
- Kelly Jenkins
- Phone Number: 706-721-1206
- Email: kejenkins@augusta.edu
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Recruiting
- Holden Comprehensive Cancer Center at the University of Iowa
-
Contact:
- Umar Farooq
- Phone Number: 319-384-8044
- Email: umar-farooq@uiowa.edu
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- Recruiting
- University of Kentucky Markey Cancer
-
Contact:
- Yvonne Taul
- Phone Number: 859-323-7628
- Email: Yvonne.Taul@uky.edu
-
Louisville, Kentucky, United States, 40207
- Recruiting
- Norton Cancer Institute
-
Contact:
- Tabby Thomas
- Phone Number: 502-899-3366
- Email: StudyStartup@NCIResearch.org
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Recruiting
- Hackensack Medical Center
-
Contact:
- Elizabeth McCarthy
- Phone Number: 412-860-6447
- Email: elizabethl.mccarthy@hmhn.org
-
Morristown, New Jersey, United States, 07960
- Recruiting
- Atlantic Health System
-
Contact:
- Amanda Hall
- Phone Number: 973-971-5235
- Email: amandamaria.hall@atlantichealth.org
-
Contact:
- Salome Greene
- Phone Number: 973-971-6373
- Email: salome.geene@atlantichealth.org
-
-
New York
-
Bronx, New York, United States, 10461
- Recruiting
- Montefiore Medical Center
-
Contact:
- Joel Victor
- Phone Number: 718-430-8761
- Email: jovictor@montefiore.org
-
New York, New York, United States, 10016
- Recruiting
- NYU Langone Health
-
Contact:
- MARK BOND
- Phone Number: 646-754-7217
- Email: Mark.Bond@nyulangone.org
-
-
Ohio
-
Cincinnati, Ohio, United States, 45242
- Recruiting
- Oncology Hematology Care
-
Contact:
- Eric Clayton
- Phone Number: 27135 513-751-2273
- Email: Eric.Clayton@usoncology.com
-
Columbus, Ohio, United States, 43210
- Recruiting
- Ohio State University James Cancer Hospital
-
Contact:
- Thomas Needham
- Phone Number: 614-293-7934
- Email: Thomas.Needham@osumc.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- University of Pennsylvania
-
Contact:
- Sunita Nasta
- Phone Number: 215-614-1846
- Email: Sunita.Nasta@pennmedicine.upenn.edu
-
Contact:
- Michael McNicholas
- Phone Number: 215-614-1846
- Email: Michael.McNicholas@pennmedicine.upenn.edu
-
-
Texas
-
Dallas, Texas, United States, 75246
- Recruiting
- Baylor Charles A. Sammons Cancer Center
-
Contact:
- Tarah Satterfield
- Phone Number: 214-818-8472
- Email: Tarah.Satterfield@BSWHealth.org
-
Houston, Texas, United States, 77030-4009
- Recruiting
- MD Anderson Cancer Center
-
Contact:
- Ly Dsouza
- Phone Number: 713-745-8614
- Email: ldsouza@mdanderson.org
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Recruiting
- Huntsman Cancer Institute at The University of Utah
-
Contact:
- Erin Peterson
- Phone Number: 801-587-4655
- Email: erin.peterson@hci.utah.edu
-
-
Washington
-
Seattle, Washington, United States, 98104
- Recruiting
- Swedish Cancer Institute
-
Contact:
- Tenzin Tsomo
- Phone Number: 206-386-2831
- Email: tenzin.tsomo@swedish.org
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Recruiting
- Medical College of Wisconsin
-
Contact:
- Roisin McAndrew
- Phone Number: 414-805-5447
- Email: rmcandrew@mcw.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age greater than or equal to 18 at the time of enrollment
- Documented diagnosis of relapsed or refractory non-Hodgkin lymphoma after prior standard of care
- Eastern Cooperative Oncology Group performance status 0 or 1
- Adequate hematologic, renal, liver, cardiac and pulmonary organ function
Exclusion Criteria:
- Prior therapy with an anti-CD19 targeting agent
- Active or chronic graft versus host disease requiring therapy
- Prior allogeneic stem cell transplantation
- Central nervous system (CNS) lymphoma, prior CNS malignancy
- Prior seizure disorder, cerebrovascular ischemia, dementia, cerebellar disease or autoimmune disease with CNS involvement.
- Primary immunodeficiency
- Current or expected need for systemic corticosteroid therapy
- Current thyroid disorder. Hypothyroidism controlled with stable hormone replacement is permitted
- Other malignancy within 2 years of study entry, except curatively treated malignancies or malignancies with low risk of recurrence
- Unwillingness to follow extended safety monitoring
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation of CB-010
Patients with relapsed or refractory non-Hodgkin lymphoma will receive CB-010 following lymphodepletion.
|
Chemotherapy for lymphodepletion
Chemotherapy for lymphodepletion
CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.
|
Experimental: Expansion of CB-010
Patients with relapsed or refractory non-Hodgkin lymphoma will receive CB-010 following lymphodepletion.
|
Chemotherapy for lymphodepletion
Chemotherapy for lymphodepletion
CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary outcome measures number of patients with dose-limiting toxicities (Part A).
Time Frame: 28 days following CB-010 infusion
|
Incidence of adverse events defined as dose-limiting toxicities with onset within 28 days after CB-010 infusion.
|
28 days following CB-010 infusion
|
Primary outcome evaluates tumor response (Part B)
Time Frame: Up to 12 months
|
The primary endpoint is objective response rate.
|
Up to 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 26, 2021
Primary Completion (Estimated)
August 1, 2025
Study Completion (Estimated)
September 1, 2025
Study Registration Dates
First Submitted
November 16, 2020
First Submitted That Met QC Criteria
November 16, 2020
First Posted (Actual)
November 20, 2020
Study Record Updates
Last Update Posted (Estimated)
March 6, 2024
Last Update Submitted That Met QC Criteria
March 5, 2024
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Fludarabine
Other Study ID Numbers
- CB10A
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaUnited States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
-
Ruijin HospitalThe First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaboratorsNot yet recruitingLymphoma | Marginal Zone Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Mucosa-Associated Lymphoid Tissue Lymphoma | Intravascular Large B-Cell Lymphoma | Extranodal Lymphoma | NK/T-Cell Lymphoma, Nasal and Nasal-TypeChina
Clinical Trials on Fludarabine
-
National Institute of Arthritis and Musculoskeletal...CompletedPsoriasis | Arthritis, PsoriaticUnited States
-
Nantes University HospitalCyceronNot yet recruiting
-
Naoyuki G. Saito, M.D., Ph.D.WithdrawnAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Acute Lymphocytic LeukemiaUnited States
-
Emory UniversityCompletedSickle Cell Disease | Bone Marrow TransplantationUnited States
-
National Institute of Arthritis and Musculoskeletal...CompletedSystemic Lupus Erythematosus | Glomerulonephritis | Lupus NephritisUnited States
-
University Hospital, CaenCNRS, UMR ISTCT 6301, LDM-TEP Groupe, GIP Cyceron, Caen, FranceCompletedUntreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma PatientsFrance
-
University of Illinois at ChicagoCompletedAcute Myeloid Leukemia | Polycythemia Vera | Multiple Myeloma | Myelofibrosis | Acute Leukemia | Chronic Myelogenous Leukemia | Aplastic Anemia | Myeloproliferative Disorder | Hodgkin's Disease | Malignant Lymphoma | Lymphocytic LeukemiaUnited States
-
Zhujiang HospitalFirst Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern... and other collaboratorsUnknownLeukemia Relapse | Chronic Graft-versus-host-disease
-
Massachusetts General HospitalTerminatedMultiple Myeloma | Hodgkin Disease | Non Hodgkin's LymphomaUnited States
-
German CLL Study GroupCompletedAnemia | Chronic Lymphocytic LeukemiaGermany